CLINICA CAYANGA


Clinical Updates
 

Clinical Daily Updates
Rodolfo T. Rafael, M.D. 
 

 

 

Alzheimer's Disease
Arthritis
Asthma
Benign Prostatic Hypertrophy
Chronic Lymphocytic Leukemia
Coronary Artery Disease
Depression
Diabetes Mellitus
Dyspepsia
Erectile Dysfunction
Fatty Liver
Gallstone
Hepatitis
Hypertension
Lung Cancer
Mesothelioma
Metabolic Syndrome
Obesity
Pneumonia
Pregnancy
Prostate Cancer
Sinusitis
Stroke
Tinnitus

Self-monitoring anticoagulation superior at preventing VTE

 
Clinical Question:
Do patients monitor and manage their oral anticoagulation at least as well as professionals?

Bottom Line:
Self-management improves the quality of oral anticoagulation. Patients capable of self-monitoring and self-adjusting therapy have fewer thromboembolic events and lower mortality than those who self-monitor alone. However, self-monitoring is not feasible for all patients, and requires identification and education of suitable candidates.

Reference:
Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006;367:404-11.

Study Design:
Meta-analysis (randomized controlled trials)

Synopsis:
Near-patient testing has made self-monitoring of anticoagulation with warfarin feasible, and several trials have suggested that such monitoring might be equal to or better than standard monitoring. We did a systematic review and meta-analysis of all randomised controlled trials that assessed the effects of self-monitoring or self-management (self-testing and self-dosage) of anticoagulation compared with standard monitoring. We searched the Cochrane Register of Controlled Trials, MEDLINE, EMBASE to April 2005, and contacted manufacturers and authors of relevant studies. Outcomes analysed were: major haemorrhage, thromboembolic events, death, tests in range, minor haemorrhage, frequency of testing, and feasibility of self-monitoring. We identified 14 randomised trials of self-monitoring: pooled estimates showed significant reductions in thromboembolic events (odds ratio 0.45, 95% CI 0.30-0.68), all-cause mortality (0.61, 0.38-0.98), and major haemorrhage (0.65, 0.42-0.99). Trials of combined self-monitoring and self-adjusted therapy showed significant reductions in thromboembolic events (0.27, 0.12-0.59) and death (0.37, 0.16-0.85), but not major haemorrhage (0.93, 0.42-2.05). No difference was noted in minor haemorrhage. 11 trials reported improvements in the mean proportion of international normalisation ratios in range.

Patient Information

Health For Life
Medical Library
Breaking Medical News
Clinical Tools
Coronary Risk Profile
Dermatology
Diabetes Corner
Evidence-Based Medicine
Free Medical Books
Free Medical Journal
History Taking and Physical Examination
Hows on Making Diagnostic Examination
Medical Journal (popular)
Medical Organizations
Medical Professional News
Neurological and Psychiatric Problems in Clinical Practice
Palm Tools
Medical Notes
Medical Physiology (Lecture)
Medical Resources
Medical Search
Online Clinical Calculator
Scientific Meeting
Online Sari- Sari Store
Please support Clinica Cayanga Medical Resources by purchasing gift items at

Introduction | Scheduling a Visit| Laboratory Work Reaching Us | Map to our Office | About the Doctors

 

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.

 ©2005-2006 Clinica Cayanga. All rights reserved.
clinica.cayanga@gmail.com